← Back to Screener
Alumis Inc. Common Stock (ALMS)
Price$24.71
Favorite Metrics
Price vs S&P 500 (26W)454.09%
Price vs S&P 500 (4W)-9.77%
Market Capitalization$3.18B
All Metrics
Book Value / Share (Quarterly)$2.88
P/TBV (Annual)4.07x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.54
Price vs S&P 500 (YTD)151.91%
Net Profit Margin (TTM)-1011.75%
EPS (TTM)$-3.00
10-Day Avg Trading Volume1.24M
EPS Excl Extra (TTM)$-3.00
EPS (Annual)$-2.86
ROI (Annual)-80.76%
Cash / Share (Quarterly)$2.95
ROA (Last FY)-59.07%
EBITD / Share (TTM)$-3.09
Operating Margin (TTM)-1105.60%
Cash Flow / Share (Annual)$-3.54
P/B Ratio10.55x
P/B Ratio (Quarterly)3.38x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)128.44x
ROA (TTM)-54.92%
EPS Incl Extra (Annual)$-2.86
Current Ratio (Annual)4.34x
Quick Ratio (Quarterly)4.24x
3-Month Avg Trading Volume2.48M
52-Week Price Return392.90%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.39
P/S Ratio (Annual)132.17x
Asset Turnover (Annual)0.06x
52-Week High$30.60
EPS Excl Extra (Annual)$-2.86
26-Week Price Return462.84%
Quick Ratio (Annual)4.24x
13-Week Price Return2.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.34x
Enterprise Value$3,089.041
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1047.34%
Cash / Share (Annual)$2.95
3-Month Return Std Dev77.60%
Net Income / Employee (TTM)$-1
ROE (Last FY)-80.76%
EPS Basic Excl Extra (Annual)$-2.86
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.00
ROI (TTM)-72.65%
P/S Ratio (TTM)132.17x
Revenue / Share (Annual)$0.28
Tangible BV / Share (Annual)$2.39
Price vs S&P 500 (52W)357.80%
Year-to-Date Return156.05%
5-Day Price Return10.97%
EPS Normalized (Annual)$-2.86
Net Profit Margin (Annual)-1011.75%
Month-to-Date Return13.44%
EBITD / Share (Annual)$-3.09
Operating Margin (Annual)-1105.60%
EPS Basic Excl Extra (TTM)$-3.00
P/TBV (Quarterly)4.07x
P/B Ratio (Annual)3.38x
Pretax Margin (TTM)-1047.34%
Book Value / Share (Annual)$2.88
Price vs S&P 500 (13W)-0.19%
Beta0.85x
Revenue / Share (TTM)$0.23
ROE (TTM)-72.65%
52-Week Low$2.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.36
4.36
4.40
4.41
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | 132.17x | — | — | — | $24.71 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Alumis Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for autoimmune disorders. Leveraging its proprietary precision data analytics platform, the company aims to replace broad immunosuppression with more specific therapeutic approaches. Its pipeline includes drug candidates targeting TYK2 and IRF5 pathways.